Todd M. Morgan Announced as Candidate for ASCO Board of Directors

Todd M. Morgan Announced as Candidate for ASCO Board of Directors

Todd M. Morgan, MD, Chief of Urologic Oncology at the University of Michigan and Co-Director of the Ronald Weiser Center for Prostate Cancer at Michigan Medicine, has been announced as a candidate for the American Society of Clinical Oncology (ASCO) Board of Directors in the Designated Surgical Oncologist category.

The position carries a four-year term and provides an opportunity for surgical oncology expertise to contribute to the Society’s leadership and governance.

With a career centered on urologic oncology, academic medicine, and the development of evidence-based clinical recommendations, Dr. Morgan brings experience in prostate cancer care, scientific education, and multidisciplinary oncology.

Advancing Urologic Oncology at the University of Michigan

Dr. Morgan currently serves as Chief of Urologic Oncology and a tenured Professor in the Department of Urology at the University of Michigan, Ann Arbor.

He also holds the position of Co-Director of the Ronald Weiser Center for Prostate Cancer at Michigan Medicine.

These appointments place him in senior leadership roles within academic urologic oncology, a field that encompasses the surgical and multidisciplinary management of cancers affecting the urinary tract and male reproductive system.

His responsibilities connect specialized clinical practice with academic medicine and the broader development of prostate cancer care.

Prostate cancer remains one of the most frequently diagnosed malignancies among men worldwide, and its management continues to evolve through advances in molecular testing, risk stratification, systemic treatment, and multidisciplinary decision-making.

Dr. Morgan’s leadership positions reflect his professional involvement in a specialty where the integration of surgical expertise and emerging clinical evidence is particularly important.

A Leadership Role in ASCO’s Genitourinary Cancer Education

Beyond his institutional appointments, Dr. Morgan has contributed to ASCO through several volunteer positions.

He previously served as Chair of the Genitourinary (GU) Cancers Symposium Program Committee, participating in the leadership of a major scientific meeting dedicated to cancers of the genitourinary system.

The symposium provides an international platform for presenting research, discussing developments in treatment, and examining clinical challenges across prostate, bladder, kidney, and other genitourinary malignancies.

The Program Committee plays an important role in shaping the scientific content of the meeting.

Dr. Morgan’s service as Chair reflects his involvement in oncology education and scientific exchange, connecting research developments with the interests of clinicians working across genitourinary cancer specialties.

Helping Shape Evidence-Based Prostate Cancer Guidelines

Dr. Morgan’s contributions to ASCO also include membership on multiple clinical practice guideline panels.

Among these are the panels addressing Molecular Biomarkers in Localized Prostate Cancer and Metastatic Castration-Sensitive Prostate Cancer.

Both areas are central to contemporary prostate cancer management.

Molecular biomarkers are increasingly relevant to discussions surrounding prognosis, risk assessment, and treatment selection in localized prostate cancer. Their appropriate clinical use requires careful evaluation of available evidence and an understanding of how molecular information may influence decision-making.

Metastatic castration-sensitive prostate cancer represents another rapidly developing area of oncology, where treatment strategies have evolved with the introduction of additional systemic therapy options and combination approaches.

ASCO’s clinical practice guidelines support clinicians by evaluating scientific evidence and developing recommendations for patient management.

Through his participation in these guideline panels, Dr. Morgan has contributed to professional discussions intended to inform evidence-based prostate cancer care.

Representing Surgical Oncology in a Multidisciplinary Era

The Designated Surgical Oncologist position on the ASCO Board of Directors provides representation for the surgical oncology perspective within the Society’s governance.

As cancer treatment becomes increasingly multidisciplinary, surgical oncologists remain central to decisions involving diagnosis, staging, local treatment, and the integration of surgery with systemic therapy and radiation oncology.

This is particularly evident in genitourinary cancers, where treatment planning often requires collaboration among urologists, medical oncologists, radiation oncologists, pathologists, and other specialists.

Dr. Morgan’s background combines surgical oncology leadership with participation in clinical guideline development and scientific programming.

His candidacy therefore reflects experience across several areas relevant to contemporary oncology practice, from specialized surgical care to the interpretation and application of clinical evidence.

The Next Chapter in ASCO Leadership

Dr. Morgan’s candidacy for the four-year Board of Directors term represents a potential extension of his previous service to ASCO.

His experience as Chair of the GU Cancers Symposium Program Committee, participation in prostate cancer guideline panels, and leadership appointments at the University of Michigan provide a foundation for potential service within the Society’s governing body.

If elected, he would bring the perspective of an academic urologic oncologist to ASCO’s Board of Directors, contributing to discussions affecting oncology practice, scientific education, and the broader cancer care community.

The election will determine the next representative for the Designated Surgical Oncologist seat, as ASCO prepares for its upcoming leadership term.

For more updates and expert insights, visit OncoDaily.

Vahe Grigoryan
Fact checked by Vahe Grigoryan MD, Editorial Director
Vahe Grigoryan
Medically reviewed by Vahe Grigoryan MD, Editorial Director